Tempest Therapeutics Inc TPST
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if TPST is a good fit for your portfolio.
News
-
Tempest Reports First Quarter 2024 Financial Results and Provides Business Update
-
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting
-
Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications
-
Tempest Reports Year End 2023 Financial Results and Provides Business Update
-
Glancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST)
-
Tempest Presents New Data at the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-tumor Activity of TPST-1120 in Multiple Cancer Types
-
Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting
Trading Information
- Previous Close Price
- $3.47
- Day Range
- $3.17–3.56
- 52-Week Range
- $0.17–9.77
- Bid/Ask
- $3.25 / $3.33
- Market Cap
- $72.21 Mil
- Volume/Avg
- 490,889 / 900,948
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 17
- Website
- https://www.tempesttx.com
Valuation
Metric
|
TPST
|
---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.68 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric
|
TPST
|
---|---|
Quick Ratio | 4.17 |
Current Ratio | 4.29 |
Interest Coverage | −20.11 |
Quick Ratio
TPST
Profitability
Metric
|
TPST
|
---|---|
Return on Assets (Normalized) | −71.00% |
Return on Equity (Normalized) | −225.80% |
Return on Invested Capital (Normalized) | −79.83% |
Return on Assets
TPST
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Ptrdzwtlwy | Kwnk | $567.0 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Hcczcdl | Thcxwg | $109.1 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Qbjnptrh | Drcvsb | $105.3 Bil | |
MRNA
| Moderna Inc | Gjsjtyfl | Gnwvg | $47.0 Bil | |
ARGX
| argenx SE ADR | Dvdcpptsx | Pndw | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Tcpqmwx | Csjdj | $22.1 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Qwtgbxyvr | Vpyxylm | $19.0 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Fmnlzxjz | Jfktlym | $15.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Pjwmwmgx | Dtgtgs | $12.7 Bil | |
INCY
| Incyte Corp | Cxsxdkcmp | Pzvwxn | $12.0 Bil |